Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Preliminary data from a study conducted at the University of Oxford suggests that the COVID-19 vaccine developed by AstraZeneca PLC is successful against the P1, or Brazilian, version, a source with knowledge of the study told Reuters on Friday.
The data suggests that the vaccine won’t need to be modified so as to safeguard against the variant, which is thought to have originated from the Amazonian city of Manaus, said the source, who requested anonymity as the results have not yet been made public.
The source did not offer the exact efficacy of the vaccine against the variant. They stated the complete results of the study should be released soon, maybe in March.
Early results indicated the AstraZeneca vaccine was less effective against the South African variant, which is very similar to P1. South Africa then stopped the usage of the vaccine in the nation.
The information comes as a small-sample study indicated the COVID-19 vaccine developed by China’s Sinovac might not work effectively against the Brazilian variant.
Responding to a request for comment, Fiocruz, that sent the samples that formed the basis of the research, told Reuters it didn’t have any information on the analysis, as it had been directed by AstraZeneca and the University of Oxford.
Agents for AstraZeneca and the University of Oxford didn’t immediately respond to requests for comment.
Brazil is presently confronting a brutal and long-lasting second wave of the coronavirus, hitting a daily record of 1,910 deaths on Wednesday.
The P1 variant is one of the factors that epidemiologists believe is contributing to a rise in deaths and cases, and there’s been concern in the scientific community concerning the variant’s immunity to vaccines.
